Sg Americas Securities, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Sg Americas Securities, LLC

  • $27.6 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024
BUY
$38.96 - $42.75 $958,065 - $1.05 Million
24,591 Added 508.81%
29,424 $1.2 Million
Q1 2024

May 06, 2024
SELL
$40.88 - $43.27 $803,455 - $850,428
-19,654 Reduced 80.26%
4,833 $204,000
Q4 2023

Jan 12, 2024
BUY
$20.27 - $42.44 $496,351 - $1.04 Million
24,487 New
24,487 $1.04 Million
Q2 2023

Jul 10, 2023
SELL
$23.9 - $35.38 $592,672 - $877,353
-24,798 Reduced 84.48%
4,556 $145,000
Q1 2023

Apr 28, 2023
BUY
$22.82 - $35.32 $338,854 - $524,466
14,849 Added 102.37%
29,354 $716,000
Q4 2022

Feb 02, 2023
BUY
$25.35 - $31.96 $108,269 - $136,501
4,271 Added 41.73%
14,505 $457,000
Q3 2022

Oct 31, 2022
SELL
$25.5 - $41.42 $240,643 - $390,880
-9,437 Reduced 47.97%
10,234 $289,000
Q2 2022

Jul 29, 2022
BUY
$20.62 - $37.15 $405,616 - $730,777
19,671 New
19,671 $520,000
Q1 2022

Apr 29, 2022
SELL
$23.5 - $35.38 $185,955 - $279,961
-7,913 Closed
0 $0
Q4 2021

Feb 07, 2022
SELL
$29.21 - $44.64 $501,097 - $765,799
-17,155 Reduced 68.43%
7,913 $257,000
Q3 2021

Nov 01, 2021
SELL
$21.26 - $38.85 $1.2 Million - $2.2 Million
-56,671 Reduced 69.33%
25,068 $740,000
Q2 2021

Aug 12, 2021
BUY
$12.56 - $29.69 $1.03 Million - $2.43 Million
81,739 New
81,739 $2.09 Million

Others Institutions Holding CERE

# of Institutions
242
Shares Held
154M
Call Options Held
2.19M
Put Options Held
3.87M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email